《大行報告》大摩首予錦欣生殖(01951.HK)「增持」評級目標價11元
摩根士丹利研究報告指錦欣生殖(01951.HK)是領先的輔助生殖服務提供商,業務遍及中國及美國。公司在成都及深圳分別有兩家醫院,並有兩家廠房。公司2016至2018年的收入及經調整純利的年複合增長率分別為63%及64%,預期2018至2021年收入及經調整純利的年複合增長率分別為40%及56%。
報告認為,公司具有長期運營歷史和信譽良好的醫生;優化運營模式的高生產率;潛在積極的中美協同效應等優勢。首次給予其「增持」投資評級,目標價11元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.